Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer
Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024
Express News | Viatris Inc: Pricing Terms for Outstanding 1.650% Senior Notes Due 2025 Issued by Viatris & Outstanding 2.125% Senior Notes Due 2025 Issued by Mylan
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Express News | Viatris Announces Cash Tender Offers for Certain Outstanding Notes